This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, Feb. 9, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. ("Zogenix") (Nasdaq:ZGNX) today announced that it has received the 2011 Drug Delivery Partnerships™ ("DDP") Innovation Award in the Industry Achievement category for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System. Winners of this year's DDP Awards, which recognize success within the drug delivery industry, were selected by attendees at the 15
th annual DDP conference, held in Miami, Florida.
SUMAVEL DosePro is the first drug product approved by the U.S. Food and Drug Administration (FDA) using the Zogenix DosePro needle-free drug delivery technology, which allows for the subcutaneous delivery of medication. SUMAVEL DosePro is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes. During the first year of production over 1,000,000 commercial units have been produced establishing the viability of a single-use, disposable, pre-filled needle-free technology for use in other important therapeutic applications.
Roger L. Hawley, Chief Executive Officer and Director of Zogenix said, "The DDP Industry Achievement Award is a significant honor at one of the pharmaceutical industry's largest drug delivery conferences. We believe it reinforces SUMAVEL DosePro as an innovative treatment for the migraine market and further validates our DosePro technology platform."
Stephen J. Farr, Ph.D., President and Chief Operating Officer said, "We believe this award recognizes the importance of our DosePro technology for the biopharmaceutical industry. The commercial experience of 2010 showed that physicians and patients alike are willing to use treatment administered subcutaneously instead of orally if it is available in an easy-to-use needle-free system like DosePro. The competitive advantage offered by the DosePro technology is now available for licensing to other biopharmaceutical firms. Clinical studies suggest that DosePro will have significant versatility in delivering various types of therapeutic compounds, including biologic products."
Zogenix and its co-promotion partner, Astellas Pharma US, Inc., launched SUMAVEL DosePro in the United States in January 2010. Zogenix has a partnership with Desitin Arzneimittel GmbH to develop and commercialize SUMAVEL DosePro in the European Union (EU). Desitin plans to launch SUMAVEL DosePro in Germany and Denmark in early 2011. Desitin is responsible for pursuing MAA approvals and broader commercialization on a country-by-country basis under the EU decentralized procedure in territories in the EU for which Desitin elects to undertake such activities.